Stem Cell Therapy for Aortic Aneurysm

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462161
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular surgery
• Research Institution: Nagoya University
• Principal Investigator: Narita Yuji 名古屋大学, 医学(系)研究科(研究院), 講師 (60378221)
• Co-Investigator(Kenkyū-buntansha): USUI AKIHIKO 名古屋大学, 医学系研究科, 教授 (30283443) ; OSHIMA HIDEKI 名古屋大学, 医学部附属病院, 講師 (40378188) ; OGATA AIKA 名古屋大学, 医学系研究科, 研究員 (70718311) ; OKADA MASAHO 名古屋大学, 医学部附属病院, 病院助教 (20566989)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 大動脈瘤 / 細胞療法 / 間葉系幹細胞 / 同種移植 / リバースリモデリング

Outline of Final Research Achievements

We have reported intravenous administration of bone marrow-derived mesenchymal stem cells (BM-MSCs) reduce the incidence of aortic aneurysm. However, optimal injected cell number, injected interval, timing of administration and optimal cell sources were unknown. In this study, we tried to explore optimal stem cell therapy for aortic aneurysm.
Intravenous administration of BM-MSCs not only prevented growth of aortic aneurysm, but conducted regression of aortic aneurysm. The aortic aneurysm was prevented by every 4 weeks administration of BM-MSC, however, it could not achieve by single administration. The regression of aortic aneurysm was maintained until 2 weeks after administration of BM-MSCs. The administration of BM-MSCs was better for regression of the aortic aneurysm than that of adipocyte-derived MSCs or fibroblast. The administration of allogenic BM-MSCs was effective treatment for aortic aneurysm as same as that of autologous BM-MSCs.

Free Research Field

心臓外科学